Skip to main content

European Nanomedicine Characterization Laboratory

Deliverables

Liaison activities with external stakeholders –final report

A final report on the Liaison activities with external stakeholders will be prepared.

3rd Data Management Plan

3rd Sample Management Report

Activities to promote innovation through partnership with industry – 2nd report

Activities to promote innovation through partnership with industry– 2nd report

Searching for OpenAIRE data...

Publications

Analytical ultracentrifugation for analysis of doxorubicin loaded liposomes

Author(s): Dora Mehn, Patrizia Iavicoli, Noelia Cabaleiro, Sven Even Borgos, Fanny Caputo, Otmar Geiss, Luigi Calzolai, François Rossi, Douglas Gilliland
Published in: International Journal of Pharmaceutics, 523/1, 2017, Page(s) 320-326, ISSN 0378-5173
Publisher: Elsevier BV
DOI: 10.1016/j.ijpharm.2017.03.046

Measuring Particle Size Distribution by Asymmetric Flow Field Flow Fractionation: A Powerful Method for the Preclinical Characterization of Lipid-Based Nanoparticles

Author(s): Fanny Caputo, Amandine Arnould, Maria Bacia, Wai Li Ling, Emilie Rustique, Isabelle Texier, Adriele Prina Mello, Anne-Claude Couffin
Published in: Molecular Pharmaceutics, 16/2, 2018, Page(s) 756-767, ISSN 1543-8384
Publisher: American Chemical Society
DOI: 10.1021/acs.molpharmaceut.8b01033

Are existing standard methods suitable for the evaluation of nanomedicines: some case studies

Author(s): Sabrina Gioria, Fanny Caputo, Patricia Urbán, Ciarán Manus Maguire, Susanne Bremer-Hoffmann, Adriele Prina-Mello, Luigi Calzolai, Dora Mehn
Published in: Nanomedicine, 13/5, 2018, Page(s) 539-554, ISSN 1743-5889
Publisher: Future Medicine Ltd.
DOI: 10.2217/nnm-2017-0338

Larger or more? Nanoparticle characterisation methods for recognition of dimers

Author(s): D. Mehn, F. Caputo, M. Rösslein, L. Calzolai, F. Saint-Antonin, T. Courant, P. Wick, D. Gilliland
Published in: RSC Advances, 7/44, 2017, Page(s) 27747-27754, ISSN 2046-2069
Publisher: Royal Society of Chemistry
DOI: 10.1039/c7ra02432k

Measuring particle size distribution of nanoparticle enabled medicinal products, the joint view of EUNCL and NCI-NCL. A step by step approach combining orthogonal measurements with increasing complexity

Author(s): F. Caputo, J. Clogston, L. Calzolai, M. Rösslein, A. Prina-Mello
Published in: Journal of Controlled Release, 299, 2019, Page(s) 31-43, ISSN 0168-3659
Publisher: Elsevier BV
DOI: 10.1016/j.jconrel.2019.02.030

Sound understanding of environmental, health and safety, clinical, and market aspects is imperative to clinical translation of nanomedicines

Author(s): Matthias Rösslein, Neill J. Liptrott, Andrew Owen, Patrick Boisseau, Peter Wick, Inge K. Herrmann
Published in: Nanotoxicology, 11/2, 2017, Page(s) 147-149, ISSN 1743-5390
Publisher: Informa Healthcare
DOI: 10.1080/17435390.2017.1279361

Multiparametric Preclinical Assessment of Theranostics Materials

Author(s): Adriele Prina-Mello
Published in: Handbook of Nanomaterials for Cancer Theranostics, 2018, Page(s) 517-535, ISBN 9780-128133392
Publisher: Elsevier
DOI: 10.1016/b978-0-12-813339-2.00017-7